热门资讯> 正文

Arrowhead Pharmaceuticals与Novartis签署了针对帕金森病等突触核蛋白病的ARO-SNCA全球许可和合作协议; Arrowhead将获得2亿美元的预付款，并且有资格获得高达20亿美元的里程碑付款加上商业销售版税

2025-09-02 19:32

Upon closing, Arrowhead will receive an upfront payment of $200 million
Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead's preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Parkinson's Disease, plus additional collaboration targets

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。